Regulatory scripting: Stakeholder participation in food and drug administration medical device advisory meetings
PLOS ONE · 16.02.2023 · 18 (2) · e0281774
DOI: 10.1371/journal.pone.0281774 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 16.02.2023. Verfasst von Shelley K White und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Public Health and Sociology, Simmons University, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Stakeholder Participation, Advisory Committees. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Simmons University Undergraduate Faculty-Student Collaborative Fellowship.
Abstract (Originalsprache)
In an age of biomedicalization, medical devices have become more common and more technologically complicated, and adverse events associated with medical devices have increased. The U.S. Food and Drug Administration (FDA) relies on advisory panels to assist in regulatory decision making regarding medical devices. Public meetings held by these advisory panels allow stakeholders to testify, presenting evidence and recommendations, according to careful procedural standards. This research examines the participation of six stakeholder groups (patients, advocates, physicians, researchers, industry representatives and FDA representatives) in FDA panel meetings focused on the safety of implantable medical devices between 2010–2020. We use qualitative and quantitative methods to analyze speakers’ opportunities for participation, bases of evidence, and recommendations, applying the concept of ‘scripting’ to understand how this participation is shaped by regulatory structures. Regression analysis demonstrates statistically significant differences in speaking time, where researchers, industry, and FDA representatives had longer opening remarks and more exchanges with FDA panelists than patients. Patients, advocates and physicians shared the least amount of speaking time, and were the parties most likely to leverage patients’ embodied knowledge and recommend the most stringent regulatory actions like recalls. Meanwhile, researchers, FDA, and industry representatives rely on scientific evidence and, with physicians, recommend actions that preserve medical technology access and clinical autonomy. This research highlights the scripted nature of public participation and the types of knowledge considered in medical device policymaking.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Departments of Public Health and Sociology, Simmons University, Boston, Massachusetts, United States of America.
- Departments of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America.
ORCID-Profile: Shelley K White
Förderung
- Simmons University Undergraduate Faculty-Student Collaborative Fellowship
Zitieren
APA
White, S. K., Leiter, V., Le, M. H., & Helms, C. K. (2023). Regulatory scripting: Stakeholder participation in food and drug administration medical device advisory meetings. PLOS ONE, 18(2), e0281774. https://doi.org/10.1371/journal.pone.0281774
Vancouver
White SK, Leiter V, Le MH, Helms CK. Regulatory scripting: Stakeholder participation in food and drug administration medical device advisory meetings. PLOS ONE. 2023;18(2):e0281774. doi:10.1371/journal.pone.0281774
BibTeX
@article{White2023,
author = {White, Shelley K and Leiter, Valerie and Le, Mi H and Helms, Caitlyn K},
title = {Regulatory scripting: Stakeholder participation in food and drug administration medical device advisory meetings},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {2},
pages = {e0281774},
doi = {10.1371/journal.pone.0281774}
}
EUVIMED